The aim of our study was to assess in our context, the efficacy of Rifaxim in improving the symptoms of irritable bowel syndrome particularly in its diarrheal (IBS-D) or mixed (IBS-DC) component and therefore assess its impact on patients’ quality of life. Patients and methods: This was an uncontrolled, non-comparative prospective cohort study of a single group of patients. Patients recruitment was done in two University Hospitals for 6 months (September 2015-February 2016). Were included ambulatory patients, male or female, aged 18 - 75 years, with diarrheic IBS (IBS-D) or mixed IBS (IBS-DC) diagnosed according to Rome III criteria and who agreed to participate in the study. Each patient received 400mg Rifaximin × 2/d for 15 days. The overall assessment of the efficacy of treatment at D15 (end of treatment) and D30 (2 weeks post-treatment) was the primary criterion of judgment. The statistical tests used were the Chi-square test and Fisher’s exact test for the qualitative variables and Student’s test for the quantitative variables. Results: A total number of 30 patients (16 women) with an average age of 44.5 ± 13.9 years were included. The overall assessment of symptoms by the patient with the Likert scale found 28 (93.3%) patients, 12 (40%) patients and 10 patients (33.3%) for a scale ≥2 at D0, D15 and D30 respectively. The assessment of the intensity of pain or abdominal discomfort found at D0, D15 and D30 respectively: 27(90%), 13(43.4%) and 6(20.1%) patients who had an EVA score > 2. The mean score for Francis to assess the improved quality of life was 247.1 ± 97.4 at D0, 99.8 ± 63.1 at D15 and 128.8 ± 70.6 at D30. Conclusion: There is a good overall improvement of symptoms in our patients suffering from IBS-D or mixed (IBS-DC) on Rifaximin with improvement of the quality of life.
KeywordsRifaximinIrritable BowelDiarrheaQuality of Life
Coffin, B. (2013) Quel est l’impact du Syndrome de l’Intestin Irritable sur la qualité de vie des patients? [What Is the Impact of Irritable Bowel Syndrome on Patients’ Quality of Life?] Hepato Gastro, 20, 11-15.
Gourcerol, G., Melchior, C., Leroi, A.M. and Ducrotté, P. (2013) Traitement du syndrome de l’intestin irritable: où en est-on? [Management of Irritable Bowel Syndrome: Current Status and Future Perspective.] Hepato-Gastro, 20, 752-765.
Ducroté, P. (2011) Microbiote et syndrome de l’intestin irritable. [Microbiota and Irritable Bowel Syndrome.] Lettre de l’hépato-gastroentérologue, XIV, 154-159.
Drossman, D.A., Li, Z., Andruzzi, E., et al. (1993) U.S. Householder Survey of Functional Gastrointestinal Disorders: Prevalence, Sociodemography, and Health Impact. Digestive Diseases and Sciences, 38, 1569-1580. https://doi.org/10.1007/BF01303162
Camilleri, M. and, Andresen, V. (2009) Current and Novel Herapeutic Options for Irritable Bowel Syndrome Management. Digestive and Liver Disease, 41, 854-862. https://doi.org/10.1016/j.dld.2009.07.009
Hammerle, C.W. and Surawicz, C.M. (2008) Updates on Treatment of Irritable Bowel Syndrome. World Journal of Gastroenterology, 14, 2639-2649. https://doi.org/10.3748/wjg.14.2639
El-Serag, H.B. (2003) Impact of Irritable Bowel Syndrome, Prevalence and Effect on Health Related Quality of Life. Reviews in Gastroenterological Disorders, 3, S3-S11.
Lembo, A.J. (2015) New and Emerging Treatment Options for Irritable Bowel-Syndrome Current and Emerging Therapies for Irritable Bowel Syndrome. Gastroenterology & Hepatology, 11, 9-15.
Bajaj, J., Heuman, D., Sanyal, A., Hylemon, P., Sterling, R., Stravitz, R. et al. (2013) Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy. PLoS One, 8, e60042. https://doi.org/10.1371/journal.pone.0060042
Brown, E., Xue, Q., Jiang, Z., Xu, Y. and DuPont, H. (2010) Pretreatment of Epithelial Cells with Rifaximin Alters Bacterial Attachment and Internalization Profiles. Antimicrob Agents Chemother, 54, 388-396. https://doi.org/10.1128/AAC.00691-09
Cheng, J., Shah, Y., Ma, X., Pang, X., Tanaka, T., Kodama, T., et al. (2010) Therapeutic Role of Rifaximin in Inflammatory Bowel Disease: Clinical Implication of Human Pregnane X Receptor Activation. Journal of Pharmacology and Experimental Therapeutics, 335, 32-41. https://doi.org/10.1124/jpet.110.170225
Debbia, E., Maioli, E., Roveta, S. and Marchese, A. (2008) Effects of Rifaximin on Bacterial Virulence Mechanisms at Supra- and Sub-Inhibitory Concentrations. Journal of Chemotherapy, 20, 186-194. https://doi.org/10.1179/joc.2008.20.2.186
Hopkins, K., Mushtaq, S., Richardson, J., Doumith,M., de Pinna, E., Cheasty, T., et al. (2014) In Vitro Activity of Rifaximin against Clinical Isolates of Escherichia coli and Other Enteropathogenic Bacteria Isolated from Travellers Returning to the UK. International Journal of Antimicrobial Agents, 45, 431-437.
Jiang, Z., DuPont, H., La Rocco, M. and Garey, K. (2010) In Vitro Susceptibility of Clostridium difficile to Rifaximin and Rifampin in 359 Consecutive Isolates at a University Hospital in Houston, Texas. Journal of Clinical Pathology, 63, 355-358. https://doi.org/10.1136/jcp.2009.071688
Jiang, Z., Ke, S. and DuPont, H. (2010) Rifaximininduced Alteration of Virulence of Diarrhoea-Producing Escherichia coli and Shigella sonnei. International Journal of Antimicrobial Agents, 35, 278-281.
Maccaferri, S., Vitali, B., Klinder, A., Kolida, S., Ndagijimana, M., Laghi, L., et al. (2010) Rifaximin Modulates the Colonic Microbiota of Patients with Crohn’s Disease: An in Vitro Approach using a Continuous Culture Colonic Model System. Journal of Antimicrobial Chemotherapy, 65, 2556-2565. https://doi.org/10.1093/jac/dkq345
Mencarelli, A., Migliorati, M., Barbanti, M., Cipriani,S., Palladino, G., Distrutti, E., et al. (2010) Pregnane-X-Receptor Mediates the Anti-Inflammatory Activities of Rifaximin on Detoxification Pathways in Intestinal Epithelial Cells. Biochemical Pharmacology, 80, 1700-1707.
Mencarelli, A., Renga, B., Palladino, G., Claudio, D., Ricci, P., Distrutti, E., et al. (2011) Inhibition of NF-kB by a PXR-Dependent Pathway Mediates Counter-Regulatory Activities of Rifaximin on Innate Immunity in Intestinal Epithelial Cells. European Journal of Pharmacology, 668, 317-324.
Schrodt, C., McHugh, E., Gawinowicz, M., DuPont, H. and Brown, E. (2013) Rifaximin-Mediated Changes to the Epithelial Cell Proteome: 2-D Gel Analysis. PLoS ONE, 8, e68550. https://doi.org/10.1371/journal.pone.0068550
Terc, J., Hansen, A., Alston, L. and Hirota, S. (2014) Pregnane X Receptor Agonists Enhance Intestinal Epithelial Wound Healing and Repair of the Intestinal Barrier Following the Induction of Experimental Colitis. European Journal of Pharmaceutical Sciences, 55, 12-19.
Xu, D., Gao, J., Gillilland, M., III, Wu, X., Song, I., Kao, J., et al. (2014) Rifaximin Alters Intestinal Bacteria and Prevents Stress-Induced Gut Inflammation and Visceral Hyperalgesia in Rats. Gastroenterology, 146, 484-496. https://doi.org/10.1053/j.gastro.2013.10.026
Foxx-Orenstein, A.E. (2016) New and Emerging Therapies for the Treatment of Irritable Bowel Syndrome: An Update for Gastroenterologists. Therapeutic Advances in Gastroenterology, 9, 354-375. https://doi.org/10.1177/1756283X16633050
Di Stefano, M., Tana, P., Mengoli, C., Miceli, E., Pagani, E. and Corazza, G. (2011) Colonic Hypersensitivity Is a Major Determinant of the Efficacy of Bloating Treatment in Constipation-Predominant Irritable Bowel Syndrome. Internal and Emergency Medicine, 6, 403-411. https://doi.org/10.1007/s11739-010-0496-0
Pimentel, M., Park, S., Mirocha, J., Kane, S.V. and Kong, Y. (2006) The Effect of a Nonabsorbed Oral Antibiotic (Rifaximin) on the Symptoms of the Irritable Bowel Syndrome: A Randomized Trial. Annals of Internal Medicine, 145, 557-563. https://doi.org/10.7326/0003-4819-145-8-200610170-00004
Pimentel, M., Lembo, A., Chey, W., Zakko, S., Ringel, Y., Yu, J., et al. (2011) Target Study Group. Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation. The New England Journal of Medicine, 364, 22-32. https://doi.org/10.1056/NEJMoa1004409
Pimentel, M., Chang, C., Chua, K., Mirocha, J., DiBaise, J., Rao, S., et al. (2014) Antibiotic Treatment of Constipation-Predominant Irritable Bowel Syndrome. Digestive Diseases and Sciences, 59, 1278-1285. https://doi.org/10.1007/s10620-014-3157-8
Sharara, A.I., Aoun, E., Abdul-Baki, H., Mounzer, R., Sidani, S. and Elhajj, I. (2006) A Randomized Double-Blind Placebo-Controlled Trial of Rifaximin in Patients with Abdominal Bloating and Flatulence. The American Journal of Gastroenterology, 101, 326-333. https://doi.org/10.1111/j.1572-0241.2006.00458.x
Ford, A., Moayyedi, P., Lacy, B., Lembo, A., Saito, Y., Schiller, L., et al. (2014) Task Force on the Management of Functional Bowel Disorders. American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation. The American Journal of Gastroenterology, 109, S2-S26. https://doi.org/10.1038/ajg.2014.187
Menees, S., Maneerattannaporn, M., Kim, H. and Chey, W. (2012) The Efficacy and Safety of Rifaximin for the Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. The American Journal of Gastroenterology, 107, 28-35. https://doi.org/10.1038/ajg.2011.355
Shah, E., Kim, S., Chong, K., Lembo, A. and Pimentel, M. (2012) Evaluation of Harm in the Pharmacotherapy of Irritable Bowel Syndrome. American Journal of Medicine, 125, 381-393.
Pimentel, M., Chow, E.J. and Lin, H.C. (2003) Normalization of Lactulose Breath Testing Correlates with Symptom Improvement in Irritable Bowel Syndrome: A Double-Blind,Randomized, Placebo-Controlled Study The American Journal of Gastroenterology, 98, 412-419.
Posserud, I., Stotzer, P., Björnsson, E., Abrahamsson, H. and Simrén, M. (2007) Small Intestinal Bacterial Overgrowth in Patients with Irritable Bowel Syndrome. Gut, 56, 802-808. https://doi.org/10.1136/gut.2006.108712
Kassinen, A., Krogius-Kurikka, L., Makivuokko, H., et al. (2007) The Fecal Microbiota of Irritable Bowel Syndrome Patients Differs Significantly from That of Healthy Subjects. Gastroenterology, 133, 24-33. https://doi.org/10.1053/j.gastro.2007.04.005
Pimentel, M. (2009) Review of Rifaximin as Treatment for SIBO and IBS. Expert Opinion on Investigational Drugs, 18, 349-358. https://doi.org/10.1517/13543780902780175
Brigidi, P., Swennen, E., Rizzello, F., Bozzolasco, M. and Matteuzzi, D. (2002) Effects of Rifaximin Administration on the Intestinal Microbiota in Patients with Ulcerative Colitis. Journal of Chemotherapy, 14, 290-295. https://doi.org/10.1179/joc.2002.14.3.290